Attachment 9B:

Survey to Determine IRB Policy Regarding NCI Action Letters

OMB No. 0925-0046-09
Expiry Date:

1. Does your IRB review Action Letters for NCI Cooperative Group Phase 2 or 3 treatment trials? Yes ___ No ___

2. Please identify your role:
   _____ IRB Administrator/Director
   _____ IRB Chair

3. Does your IRB allow expedited review for Action Letters?
   ___ Always ____ Sometimes ____ Never

4. If your IRB does not allow Action Letters to receive expedited review, why not? (answer all that apply)

   ____Was not aware OHRP allows it

   ____OHRP written statement confusing

   ____IRB office wants to process all Action Letters the same way regardless of level of risk

   ____Individuals who conduct expedited review do not have sufficient oncology expertise

   ____Other, explain: _____

5. To the best of your knowledge, are patients at your institution not enrolled on trials due Action Letters resulting in temporary suspension? ___ Yes ___ No